Drug Delivery

Glaukos has struck a deal to license iVeena Delivery Systems’ IVMED-80, paying $10 million upfront for the global rights to the disease modifying topical eye drop candidate that completed a phase 1/2a trial last year.

The Bill & Melinda Gates Foundation is bankrolling Celanese’s work to develop a refillable long-acting implant for delivery of a contraceptive drug, committing $625,800 to support the creation of a functional prototype.

It’s the 20th year we’ve sought out the most innovative private biotechs, which also means we've entered the second decade we've been checking in on our past honorees.

This week on "The Top Line," we discuss Genentech’s Greg Rippon's remarks on missing the mark in terms of diverse trial recruitment and how the company hopes to get it right in the future. We'll also chat about a new report on brand awareness for diabetes drugs.

Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success.

Set a solid foundation for successful scale-up of buffer preparation.

See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead.

What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations?

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?

Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound.

How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market?

Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry.

Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays?

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.